Missing Informed Consent for Psychotropic Medications
Summary
The facility failed to obtain documented informed consent for psychotropic medications for 5 of 5 residents reviewed for unnecessary medications. The report identified missing consents for antidepressants, antipsychotics, and other psychotropic medications when they were initiated and, in some cases, when doses were increased or medications were switched. The Director of Nursing stated that some informed consents for psychotropic medications had not been completed and that consents should have been obtained when the medications were initiated or increased. Resident 53 had diagnoses including major depressive disorder and unspecified psychosis, with moderate cognitive deficit noted on the quarterly MDS. The resident received duloxetine in multiple dose changes, Lexapro, Invega, and later olanzapine, but the record lacked documentation of informed consent for the antidepressant medications when they were initiated or increased. A document in the chart also indicated no informed consent was found for duloxetine. Resident 11 had diagnoses including unspecified mood disorder and bipolar disorder, with no cognitive deficit noted on the quarterly MDS. The resident received fluoxetine for depression and quetiapine for bipolar disorder, but the record lacked documentation of informed consent for the antidepressant medication and for the initiation and/or increase of the antipsychotic medication. Resident 10 had insomnia and mania, with moderate cognitive impairment on the quarterly MDS, and received trazodone and divalproex sodium; the electronic record lacked documentation that informed consent was obtained when these medications were initiated. Resident 74 had dementia, COPD, and diabetes, and the record indicated a psychotropic medication had been ordered without consent from the responsible party. The resident received sertraline at different doses and later duloxetine, and the chart included a pharmacy recommendation stating no informed consent was found for sertraline. Resident 47 had manic episode, depression, and vascular dementia, with severe cognitive impairment on the quarterly MDS, and received Seroquel at different doses for behavioral disturbance and manic episodes. A pharmacy recommendation stated no informed consent was found in the chart for Seroquel, and the electronic record lacked documentation that psychotropic informed consent was obtained for its use.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release August 26, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.